

Real-world Experience of Long-acting Triptorelin in Prostate Cancer Management



YH Chung, CH Ko, HM Wong, A Mok, PKF Chiu, JYC Teoh, CH Yee, CF Ng

S.H. Ho Urology Centre, Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong

Objective

Long-acting triptorelin (LAT) with a 6-monthly injection regime is a gonadotropin-releasing hormone (GnRH) agonist used in men with prostate cancer. This study investigated the prescription pattern of LAT in the real-world setting.

Methods

It was a retrospective review of patients prescribed with LAT for prostate cancer since its introduction to the territory in January 2018 to March 2023 in a tertiary center. Demographic data were collected and LAT prescription pattern were reviewed. These included indication and duration of prescription, testosterone suppression as well as characteristics of the primary prostate cancer.


Patients & Result

A total of 237 prostate cancer patients were prescribed with LAT in the study period. 88% of patient presented with clinically significant prostate cancer with ISUP ≥ 2 . The median age of LAT first dose and the median treatment duration were 72 (53-94) years and 42 (6-72) months respectively. A total of 58 (25%) patients had their testosterone level checked after commencing LAT. The median time interval of testosterone check after starting LAT was 8 (1-47) months, with 98.3% having testosterone < 1.7 nmol/L and 94.9% < 0.7 nmol/L.


Indication of ADT



Treatment before Long Acting Triptorelin



92% Did Not change to another form of hormonal treatment other than LAT.



Successful Castration with

98.3% [Testosterone] level < 1.7 nmol/L

94.9% [Testosterone] level < 0.7 nmol/L.

Conclusion

LAT had a high adherence rate in the setting of prostate cancer hormonal treatment. Testosterone suppression was satisfactory after commencement of LAT.